• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can Eating Chocolate Lower Risk for Preeclampsia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:  

  • Flavenols found in dark chocolate have antioxidant effects and promote direct nitric-oxide dependent vasodilation  
  • Meta-analyses of RCTs have demonstrated that chocolate can lead to a reduction in blood pressure  
    • Data specific to preeclampsia prevention is inconsistent and studies
      have primarily been observational rather than randomized
  • Babar et al. (Hypertension in Pregnancy, 2018) sought to determine the impact of a high flavanol high theobromine (HFHT) chocolate diet on the health of women at risk of preeclampsia 

METHODS:  

  • Double blind single-center randomized control trial (RCT)  
  • Participants: Women at risk for preeclampsia between 18 and 38 years of age  
  • Risk of preeclampsia was determined during routine Doppler between 11 and 14 weeks gestation with bilateral uterine artery diastolic notches and  
    • Uterine artery pulsatility index (UtA PI) > 95th percentile on one side and/or bilateral UtA PI > 50th percentile  
  • Women were randomized into two groups  
    • High flavanol high theobromine (HFHT) chocolate  
    • Low flavanol low theobromine (LFLT) chocolate  
  • Changes in plasma flavanol and theobromine (methylxanthine compound found in cacao seeds, chemically similar to caffeine), peripheral arterial tonometry and blood pressure (BP) were assessed  
    • Acute phase: At 0, 60 and 120 minutes after 40 g dose of chocolate  
    • Chronic phase: At 6 and 12 weeks, following daily intake of 30 g of chocolate (10 g chocolate three times a day with meals) 
  • Reactive hyperemia index (RHI) was used as a marker for endothelial function and adjusted augmentation index (AIx)  was used as a marker for arterial stiffness 

RESULTS:  

  • 131 pregnant women were involved in the study  
  • Compared to LFLT, acute HFHT intake significantly 
    • Increased theobromine (p < 0.0001), both initially and chronic intake  
    • Decreased AIx (p < 0.0001)  
    • Increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group; p = 0.0008)  
    • There was no change in endothelial function  
  • Rates of pregnancy induced hypertension 
    • Without preeclampsia: 3% in the HFHT group vs 6% in LFLT group and was not significantly different (p=0.44) 
    • With preeclampsia: 1.5% in HFHT group vs 6.1% in LFLT group and was not significantly different (p=0.21)   
  • No other significant differences within group or between group changes were observed  

CONCLUSION:  

  • Acute consumption of HFHT 
    • Increased levels of theobromine and decreased arterial stiffness
    • No changes in endothelial function  
    • No changes in acute systolic BP, but there was a significant increase in diastolic BP  
  • Chronic consumption 
    • Theobromine concentrations were elevated 
    • There were no differences in BP between groups at 12 weeks  
  • Neither chronic or acute HFHT chocolate diet had a clinically significant impact on endothelial function, arterial stiffness, or BP compared to LFLT in women at risk for preeclampsia
  • These results do not validate positive results of previous observational and cohort studies 

Learn More – Primary Sources:  

Changes in endothelial function, arterial stiffness and blood pressure in pregnant women after consumption of high-flavanol and high-theobromine chocolate: a double blind randomized clinical trial.

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG and USPSTF Recommendations  
Results from the SPREE Trial: How Does First Trimester Preeclampsia Screening Compare to Current Guidelines?
Which Markers Can We Use to Screen for Early and Late Preeclampsia?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site